Orpathys–Tagrisso combination enters US FDA application stage
AstraZeneca has submitted a US new drug application for Orpathys with Tagrisso in a specified group of people with advanced lung cancer after prior EGFR-targeted treatment, according to reports by Mugglehead and RTTNews. HUTCHMED, AstraZeneca’s development partner, announced the filing. Submission starts a regulatory process; the FDA has not approved the combination or announced an application decision.
Science··Night
An application, not an authorization
AstraZeneca submitted a new drug application to the US Food and Drug Administration for Orpathys together with Tagrisso, according to separate reports from Mugglehead and RTTNews. HUTCHMED, which develops Orpathys with AstraZeneca, announced the submission. The filing asks the agency to consider a new use for the combination; it does not put that use on the US market. Mugglehead distinguishes submission from acceptance for formal review, and RTTNews says the FDA will decide whether to accept the application. Neither report gives an FDA approval or a decision date.[1], [2], [3]
A selected group after earlier treatment
The application concerns locally advanced or metastatic non-small-cell lung cancer after progression on or after an EGFR-targeted medicine. The tumor must show MET overexpression or amplification, according to the partners’ announcement and Mugglehead’s account. RTTNews also describes an advanced lung cancer group whose disease progressed after EGFR-targeted treatment. That selection matters: this is a request for a defined later treatment setting, not a proposal for every person with lung cancer. The reports describe a regulatory filing and its intended scope, not a recommendation for any patient to change care.[1], [2], [3]
Review still lies ahead
HUTCHMED points to its development program as support for the application, while RTTNews notes that detailed study results are scheduled for presentation later. Those statements accompany the filing; the filing reports do not provide a basis here to judge the size of any benefit or the combination’s safety. The immediate next public milestone is whether the FDA accepts the application for formal review. An acceptance would still be separate from a decision to authorize the treatment. Until the agency acts, the US request remains a proposal for a defined use of two medicines.[1], [2], [3]
